Methylation of tumor associated genes in tissue and plasma samples from liver disease patients

Experimental and Molecular Pathology

Volumn 85, Issue 2, 2008, Pages 96-100

  Chang, Hong ^a,d   Yi, Bin ^a,d   Li, Li ^b,d   Zhang, Hong Yu ^b   Sun, Feng ^c   Dong, Shu Qiang ^b   Cao, Yi ^a,d  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b Kunming First People Hospital   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d Center of Disease Control of Yunnan   (China)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Hypermethylation; Methylation specific PCR; Plasma DNA

Indexed keywords

ALPHA FETOPROTEIN; APC PROTEIN; BIOCHEMICAL MARKER; DNA; GLUTATHIONE TRANSFERASE P1; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; PLASMA; POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED GENE; TUMOR SUPPRESSOR GENE;

CADHERINS; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; GENE FREQUENCY; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; OLIGOPEPTIDES; TUMOR SUPPRESSOR PROTEINS;

HEPATITIS B VIRUS;

EID: 52149102033     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.07.001     Document Type: Article

References (26)

1. Chan K.C., Zhang J., Chan A.T., Lei K.I., Leung S.F., Chan L.Y., Chow K.C., and Lo Y.M. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 63 (2003) 2028-2032
2. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
3. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., and Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59 (1999) 67-70
4. Fleischhacker M., and Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta. 1775 (2007) 181-232
5. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
6. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93 (1996) 9821-9826
7. Iwata N., Yamamoto H., Sasaki S., Itoh F., Suzuki H., Kikuchi T., Kaneto H., Iku S., Ozeki I., Karino Y., Satoh T., Toyota J., Satoh M., Endo T., and Imai K. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19 (2000) 5298-5302
8. Kanai Y., Ushijima S., Tsuda H., Sakamoto M., and Hirohashi S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett. 148 (2000) 73-80
9. Kondo Y., Kanai Y., Sakamoto M., Mizokami M., Ueda R., and Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 32 (2000) 970-979
10. Kumada T., Nakano S., Takeda I., Sugiyama K., Osada T., Kiriyama S., Sone Y., Toyoda H., Shimada S., Takahashi M., and Sassa T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25 (1997) 87-92
11. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J., and Kang G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163 (2003) 1371-1378
12. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min D.S., and Jang K.L. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 24 (2005) 6617-6625
13. Li H.P., Leu Y.W., and Chang Y.S. Epigenetic changes in virus-associated human cancers. Cell Res. 15 (2005) 262-271
14. Liew C.T., Li H.M., Lo K.W., Leow C.K., Chan J.Y., Hin L.Y., Lau W.Y., Lai P.B., Lim B.K., Huang J., Leung W.T., Wu S., and Lee J.C. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18 (1999) 789-795
15. Liu J., Lian Z., Han S., Waye M.M., Wang H., Wu M.C., Wu K., Ding J., Arbuthnot P., Kew M., Fan D., and Feitelson M.A. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 25 (2006) 1008-1017
16. Liu K., Zhan M., and Zheng P. Loss of p73 expression in six non-small cell lung cancer cell lines is associated with 51′CpG island methylation. Exp. Mol. Pathol. 84 (2007) 59-63
17. Ryan J.L., Fan H., Swinnen L.J., Schichman S.A., Raab-Traub N., Covington M., Elmore S., and Gulley M.L. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn. Mol. Pathol. 13 (2004) 61-68
18. Shotelersuk K., Khorprasert C., Sakdikul S., Pornthanakasem W., Voravud N., and Mutirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin. Cancer Res. 6 (2000) 1046-1051
19. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., Heimbürger O., Barany P., Alvestrand A., Nordfors L., Qureshi A.R., Ekström T.J., and Schalling M. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. J. Intern. Med. 261 (2007) 488-499
20. Su P.F., Lee T.C., Lin P.J., Lee P.H., Jeng Y.M., Chen C.H., Liang J.D., Chiou L.L., Huang G.T., and Lee H.S. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int. J. Cancer. 121 (2007) 1257-1264
21. Tang Z.Y. Treatment of hepatocellular carcinoma. Digestion 59 (1998) 556-562 (in Chinese)
22. Valinluck V., and Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67 (2007) 946-950
23. Wong I.H., Lo Y.M., Zhang J., Liew C.T., Ng M.H., Wong N., Lai P.B., Lau W.Y., Hjelm N.M., and Johnson P.J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59 (1999) 71-73
24. Wong I.H., Lo Y.M., Yeo W., Lau W.Y., and Johnson P.J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6 (2000) 3516-3521
25. Yang B., Guo M., Herman J.G., and Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163 (2003) 1101-1107
26. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., Wang L.Y., Chen S.Y., Chen C.J., and Santella R.M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 13 (2007) 2378-2384